Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1

Antiviral Research

Volumn 94, Issue 3, 2012, Pages 276-287

  An, Tai ^a   Ouyang, Wenjie ^a   Pan, Wei ^a   Guo, Deyin ^a   Li, Jurong ^b   Li, Longlong ^b   Chen, Gang ^b   Yang, Jian ^b   Wu, Shuwen ^a   Tien, Po ^a  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Amino acid derivatives of the ( ) enantiomer of gossypol; Fusion inhibitor; Gp41; HIV 1

Indexed keywords

2 AMINO 2 METHYLPROPIONIC ACID; ALANINE; ALIPHATIC COMPOUND; AMINO ACID DERIVATIVE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GOSSYPOL DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; ISOLEUCINE; LEUCINE; RNA DIRECTED DNA POLYMERASE; VALINE;

ANTIGEN BINDING; ARTICLE; CELL FUSION; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; ENANTIOMER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

AMINO ACIDS; CELL LINE; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GOSSYPOL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PROTEIN BINDING; VIRUS INTERNALIZATION; VIRUS REPLICATION;

GOSSYPIUM HIRSUTUM; HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 84861229199     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.02.014     Document Type: Article

References (67)

1. Anon., 1978. Gossypol - a new antifertility agent for males. Chin. Med. J. (Engl.) 4, 417-428.
2. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17:657-700.
3. Bonhaus D.W., Chang L.K., Kwan J., Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 1998, 287:884-888.
4. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93:681-684.
5. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
6. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 1998, 95:15613-15617.
7. Chen C.H., Matthews T.J., McDanal C.B., Bolognesi D.P., Greenberg M.L. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. 1995, 69:3771-3777.
8. Cioffi M., Hunter C.A., Packer M.J., Pandya M.J., Williamson M.P. Use of quantitative (1)H NMR chemical shift changes for ligand docking into barnase. J. Biomol. NMR 2009, 43:11-19.
9. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 1998, 4:72-77.
10. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-4732.
11. Dorsett P.H., Kerstine E.E., Powers L.J. Letter: antiviral activity of gossypol and apogossypol. J. Pharm. Sci. 1975, 64:1073-1075.
12. Eckert D.M., Malashkevich V.N., Kim P.S. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J. Mol. Biol. 1998, 284:859-865.
13. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., Kim P.S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999, 99:103-115.
14. Fauci A.S. HIV and AIDS: 20 years of science. Nat. Med. 2003, 9:839-843.
15. Gonzalez E., Ballana E., Clotet B., Este J.A. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS 2011, 25:1557-1583.
16. Gonzalez-Ortega E., Ballana E., Badia R., Clotet B., Este J.A. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antiviral Res. 2011, 92:479-483.
17. Hoffer A.P., Agarwal A., Meltzer P., Herlihy P., Naqvi R.H., Lindberg M.C., Matlin S.A. Ultrastructural, fertility, and spermicidal studies with isomers and derivatives of gossypol in male hamsters. Biol. Reprod. 1987, 37:909-924.
18. Hu Q., Trent J.O., Tomaras G.D., Wang Z., Murray J.L., Conolly S.M., Navenot J.M., Barry A.P., Greenberg M.L., Peiper S.C. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 2000, 302:359-375.
19. Hu Q., Napier K.B., Trent J.O., Wang Z., Taylor S., Griffin G.E., Peiper S.C., Shattock R.J. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J. Mol. Biol. 2005, 350:699-712.
20. Huang L., Zhang L., Chen C.H. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. Curr. Pharm. Des. 2003, 9:1453-1462.
21. Jiang S., Lin K., Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 1998, 72:10213-10217.
22. Jiang S., Lin K., Zhang L., Debnath A.K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 1999, 80:85-96.
23. Jiang S., Lu H., Liu S., Zhao Q., He Y., Debnath A.K. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 2004, 48:4349-4359.
24. Keller P.A., Birch C., Leach S.P., Tyssen D., Griffith R. Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor. J. Mol. Graph. Model. 2003, 21:365-373.
25. Kuritzkes D.R. HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 2009, 4:82-87.
26. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003, 348:2175-2185.
27. Lin T.S., Schinazi R., Griffith B.P., August E.M., Eriksson B.F., Zheng D.K., Huang L.A., Prusoff W.H. Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol. Antimicrob. Agents Chemother. 1989, 33:2149-2151.
28. Lin T.S., Schinazi R.F., Zhu J., Birks E., Carbone R., Si Y., Wu K., Huang L., Prusoff W.H. Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol. Biochem. Pharmacol. 1993, 46:251-255.
29. Lin P.F., Blair W., Wang T., Spicer T., Guo Q., Zhou N., Gong Y.F., Wang H.G., Rose R., Yamanaka G., Robinson B., Li C.B., Fridell R., Deminie C., Demers G., Yang Z., Zadjura L., Meanwell N., Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 2003, 100:11013-11018.
30. Liu S., Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr. Pharm. Des. 2004, 10:1827-1843.
31. Liu S., Zhao Q., Jiang S. Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides 2003, 24:1303-1313.
32. Liu S., Lu H., Niu J., Xu Y., Wu S., Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 2005, 280:11259-11273.
33. Liu S., Lu H., Zhao Q., He Y., Niu J., Debnath A.K., Wu S., Jiang S. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim. Biophys. Acta 2005, 1723:270-281.
34. Liu S., Wu S., Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des. 2007, 13:143-162.
35. Lu M., Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 1997, 15:465-471.
36. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995, 2:1075-1082.
37. Manmade A., Herlihy P., Quick J., Duffley R.P., Burgos M., Hoffer A.P. Gossypol. Synthesis and in vitro spermicidal activity of isomeric hemigossypol derivatives. Experientia 1983, 39:1276-1277.
38. Martinez-Irujo J.J., Villahermosa M.L., Mercapide J., Cabodevilla J.F., Santiago E. Analysis of the combined effect of two linear inhibitors on a single enzyme. Biochem. J. 1998, 329(Pt 3):689-698.
39. Matlin K.S., Reggio H., Helenius A., Simons K. Pathway of vesicular stomatitis virus entry leading to infection. J. Mol. Biol. 1982, 156:609-631.
40. McKnight A., Wilkinson D., Simmons G., Talbot S., Picard L., Ahuja M., Marsh M., Hoxie J.A., Clapham P.R. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 1997, 71:1692-1696.
41. Mondor I., Ugolini S., Sattentau Q.J. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 1998, 72:3623-3634.
42. Moulard M., Lortat-Jacob H., Mondor I., Roca G., Wyatt R., Sodroski J., Zhao L., Olson W., Kwong P.D., Sattentau Q.J. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 2000, 74:1948-1960.
43. Neurath A.R., Jiang S., Strick N., Lin K., Li Y.Y., Debnath A.K. Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nat. Med. 1996, 2:230-234.
44. Pang W., Wang R.R., Yang L.M., Liu C.M., Tien P., Zheng Y.T. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology 2008, 377:80-87.
45. Polsky B., Segal S.J., Baron P.A., Gold J.W., Ueno H., Armstrong D. Inactivation of human immunodeficiency virus in vitro by gossypol. Contraception 1989, 39:579-587.
46. Pusch O., Kalyanaraman R., Tucker L.D., Wells J.M., Ramratnam B., Boden D. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 2006, 20:1917-1922.
47. Radloff R.J., Deck L.M., Royer R.E., Vander Jagt D.L. Antiviral activities of gossypol and its derivatives against herpes simplex virus type II. Pharmacol. Res. Commun. 1986, 18:1063-1073.
48. Roberts G.C.K. NMR of macromolecules: a practical approach 1993, IRL Press at Oxford University Press, Oxford.
49. Root M.J., Kay M.S., Kim P.S. Protein design of an HIV-1 entry inhibitor. Science 2001, 291:884-888.
50. Royer R.E., Mills R.G., Deck L.M., Mertz G.J., Vander Jagt D.L. Inhibition of human immunodeficiency virus type I replication by derivatives of gossypol. Pharmacol. Res. 1991, 24:407-412.
51. Royer R.E., Deck L.M., Vander Jagt T.J., Martinez F.J., Mills R.G., Young S.A., Vander Jagt D.L. Synthesis and anti-HIV activity of 1,1'-dideoxygossypol and related compounds. J. Med. Chem. 1995, 38:2427-2432.
52. Sonenberg M., Huang J.T., Ren Y.F., Su T.L., Watanabe K.A., Haspel H.C., Corin R.E., Hoffer A.P. Anti-fertility and other actions of gossypol analogues. Contraception 1988, 37:247-255.
53. Tan K., Liu J., Wang J., Shen S., Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 1997, 94:12303-12308.
54. Tien P.C. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am. J. Gastroenterol. 2005, 100:2338-2354.
55. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010, 85:91-100.
56. Vichkanova S.A., Oifa A.I., Goriunova L.V. Antiviral properties of gossypol in experimental influenza pneumonia. Antibiotiki 1970, 15:1071-1073.
57. Wang H., Qi Z., Guo A., Mao Q., Lu H., An X., Xia C., Li X., Debnath A.K., Wu S., Liu S., Jiang S. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob. Agents Chemother. 2009, 53:4987-4998.
58. Wang H., Qi Z., Guo A., Mao Q., Lu H., An X., Xia C., Li X., Debnath A.K., Wu S., Liu S., Jiang S. ADS-J1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the gp41 Pocket Region and Blocking Fusion-Active gp41 Core Formation. Antimicrob. Agents Chemother. 2009, 53:4987-4998.
59. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
60. Welch B.D., VanDemark A.P., Heroux A., Hill C.P., Kay M.S. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA 2007, 104:16828-16833.
61. Wichmann K., Vaheri A., Luukkainen T. Inhibiting herpes simplex virus type 2 infection in human epithelial cells by gossypol, a potent spermicidal and contraceptive agent. Am. J. Obstet. Gynecol. 1982, 142:593-594.
62. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 1994, 91:9770-9774.
63. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
64. Zhao Q., Ernst J.T., Hamilton A.D., Debnath A.K., Jiang S. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retroviruses 2002, 18:989-997.
65. Zhao Q., He Y., Alespeiti G., Debnath A.K. A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Virology 2004, 326:299-309.
66. Zhao Q., Ma L., Jiang S., Lu H., Liu S., He Y., Strick N., Neamati N., Debnath A. Identification of -phenyl-'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339:213-225.
67. Zhao Q., Ma L., Jiang S., Lu H., Liu S., He Y., Strick N., Neamati N., Debnath A.K. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339:213-225.